Thor Medical ASA has signed Letters of Intent (LOI) with three radiopharmaceutical companies for future supply of alpha emitters. The LOI's signed to date are with radiopharmaceutical companies developing novel cancer therapies, one US-based and two Scandinavian companies. All companies have advanced to clinical trials for their products.

Given the successful outcome of the clinical trials, which will bring the drugs to market, the estimated future demand for alpha emitters from these potential customers exceeds the initial planned production capacity of Thor Medical's first industrial-scale manufacturing facility.